NANJING, China, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The 14th Suzhou Creative and Design Cultural Industry Expo came to an end on November 2nd. This cultural gala rooted in the Jiangnan region (the southern area of the Yangtze River Delta in China), with the core theme of "Culture and Creativity Make Life More Interesting", set a new historical high in terms of exhibition scale, number of visitors and achievements - within the 41,000-square-meter exhibition hall, there were over 100,000 person-times of visits ...

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, is pleased to announce a non-brokered private placement of up to approximately 30,000,000 units (“Units”) of the Company at a price of $0.025 per Unit for aggregate gross proceeds of up to appr ...

Revenue of $53.1 million, up 5% year over year, above the midpoint of guidancePositive adjusted EBITDA of $1.1 million or 2% adjusted EBITDA marginContinued to generate cash from operationsExpansion of Apollo and Atlas MAX PLUS installations, driving growth in bulk apparel productionAnnual recurring revenue from AIC grew to $21.5 million in Q3 and $23.1 million to date, reflecting continued adoption of Kornit’s usage-based revenue model ROSH-HA`AYIN, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Kornit Digital ...

The Aerostream BUCs are designed to enable robust, high-speed In-Flight Connectivity across both LEO and GEO satellitesPETAH TIKVA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today that its Commercial Division received an order of $7 million for Gilat Wavestream’s Aerostream 60W Ka-band Wideband BUCs. These units will be deployed as part of a next-generation In-Fl ...

融资活动概述 - 公司宣布以每股10.50美元的价格承销发行7,142,857股A类普通股 [1] - 此次发行的总收益（在扣除承销折扣和佣金及其他发行费用前）预计约为7500万美元 [1] - 发行预计于2025年11月6日左右完成，需满足惯例成交条件 [1] 资金用途 - 发行所得净收益将连同公司现有现金、现金等价物和有价证券，用于资助sonelokimab的研发以及一般公司用途 [2] 公司业务与产品管线 - 公司是一家临床阶段生物技术公司，专注于解决炎症性皮肤和关节疾病领域未满足的重大医疗需求 [1][5] - 核心产品sonelokimab是一种新型三特异性纳米抗体，可抑制IL-17A和IL-17F，在临床试验中显示出驱动皮肤病学和风湿病学患者疾病缓解的潜力 [5] - 公司聚焦于存在重大未满足需求的炎症性疾病，包括化脓性汗腺炎、银屑病关节炎、中轴型脊柱关节炎和掌跖脓疱病，这些疾病影响全球数百万人 [5] 发行相关方与文件 - Leerink Partners担任此次发行的唯一账簿管理人 [2] - 与此类证券相关的货架注册声明已提交给美国证券交易委员会，并于2023年9月11日生效 [3]

MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, November 12, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate i ...

临床数据亮点 - 在12周治疗后期，nimacimab（200mg，每周皮下注射）联合司美格鲁肽相比单用司美格鲁肽显著减缓了体重反弹，体重反弹率分别为18.1%和49.8% [2] - 治疗结束12周后，nimacimab联合司美格鲁肽组相比安慰剂组仍维持显著的体重减轻（p=0.006），而单用司美格鲁肽组相比安慰剂组则失去显著性（p=0.12） [2] - 此前报告结果显示，在26周治疗期内，nimacimab联合司美格鲁肽相比单用司美格鲁肽实现了额外的体重减轻，分别为-13.2%和-10.25%（p=0.0372），且未观察到平台期 [2] - 在腰围变化这一关键次要终点上，nimacimab联合司美格鲁肽组的最小二乘均值（标准误）变化为-11.26厘米（1.16厘米），单用司美格鲁肽组为-8.09厘米（1.2厘米），组间差异为-3.17厘米（1.59厘米）（p=0.0492） [3] 公司策略与产品定位 - 公司认为nimacimab联合疗法能够减缓患者停止GLP-1激动剂（如司美格鲁肽）治疗后通常出现的体重反弹，这在临床上意义重大 [3] - nimacimab的目标产品定位可能满足肥胖治疗范式中的多种需求，不仅可作为非肠促胰岛素类的附加或联合疗法，也可能用于维持治疗阶段 [3] - 尽管nimacimab单药治疗未导致显著体重减轻，但公司对其与司美格鲁肽联合使用在26周内达到的减重效果感到鼓舞，该效果与替尔泊肽及其他肠促胰岛素组合疗法相当，且未增加安全性问题 [3] - 公司下一步发展计划始终聚焦于进行剂量范围研究，以确定nimacimab在单药和联合治疗中的最佳剂量 [3] 公司背景与研发进展 - Skye Bioscience是一家临床阶段生物技术公司，专注于通过调节G蛋白偶联受体来开发针对肥胖及其他代谢健康疾病的新一代疗法 [1][4] - 公司主要候选药物nimacimab是一种外周限制性CB1抑制性抗体，目前正在进行针对肥胖的2a期临床试验，该试验也正在评估nimacimab与GLP-1R激动剂的联合用药 [1][4][5] - 公司将于2025年11月7日在ObesityWeek 2025大会上以最新突破性口头报告形式公布其CBeyond™ 2期概念验证研究的顶线数据 [1]

Strong third quarter financial results reflect the benefits of general rate cases and disciplined cost management.Affirming earnings guidance, with Avista Utilities expected to deliver earnings at the upper end of its range and consolidated results anticipated to be near the lower end of the range.2025 RFP shortlist selected, including Avista ownership options. SPOKANE, Wash., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Avista Corp. (NYSE: AVA) today reported third quarter 2025 financial results. Third quarter net in ...

公司股票回购计划 - 董事会授权增加1200万美元用于股票回购计划 [1] - 公司已完成第一期500万美元的回购，于8月至10月期间回购了54万股股票 [2] - 回购可通过公开市场交易、私下协商交易或其他方式进行，具体时间、频率和金额由董事会财务委员会酌情决定 [2] 公司战略与财务状况 - 公司正执行重燃增长和提高盈利能力的计划，认为其资产轻型特许经营模式、增长机会和长期估值未在当前股价中得到充分体现 [2] - 此次扩大回购授权彰显了公司致力于通过严格的资本配置为股东创造价值的承诺 [2] 公司业务概览 - 公司是全国最大的整脊护理提供商，通过The Joint Chiropractic网络运营 [3] - 公司采用零售医疗商业模式，旨在使优质护理变得方便且负担得起，无需保险 [3] - 公司总部位于斯科茨代尔，在全国拥有超过950个地点，每年患者访问量超过1400万次 [3] 公司业务结构 - 公司是诊所的特许经营商，并在某些州直接运营诊所 [4] - 在多个指定州，公司及其特许经营商为附属的专业整脊诊所提供管理服务 [4]

Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: AN ...